2024
Overall survival (OS) in a u.s. Asian population with stage IV NSCLC with EGFR mutations treated with first-line (1L) osimertinib (Osi) compared to earlier generation (Gen) of TKIs or sequential treatment (Tx).
Liu Y, Ma Z, Moreira A, Chachoua A, Velcheti V, Lau S, Punekar S, Sabari J, Shum E. Overall survival (OS) in a u.s. Asian population with stage IV NSCLC with EGFR mutations treated with first-line (1L) osimertinib (Osi) compared to earlier generation (Gen) of TKIs or sequential treatment (Tx). Journal Of Clinical Oncology 2024, 42: e20597-e20597. DOI: 10.1200/jco.2024.42.16_suppl.e20597.Peer-Reviewed Original ResearchNon-small-cell lung cancerTyrosine kinase inhibitorsStage IV non-small-cell lung cancerIV non-small-cell lung cancerOverall survivalCox proportional-hazards modelRetrospective studyProportional-hazards modelMedian OSMetastatic non-small-cell lung cancerHazard ratioIRB-approved retrospective studyMultivariate Cox proportional-hazards modelProgression-free survivalYears of follow-upKaplan-Meier methodLog-rank testAssess survival differencesCalculate hazard ratiosFLAURA trialL858R patientsNSCLC ptsSequential afatinibSuperior OSEGFR mutationsConsolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study
Nassar A, Kim S, Aredo J, Feng J, Shepherd F, Xu C, Kaldas D, Gray J, Dilling T, Neal J, Wakelee H, Liu Y, Lin S, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron T, Thummalapalli R, Yu H, Owen D, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris J, Nagasaka M, Ayanambakkam A, Velazquez A, Ragavan M, Lin J, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar S, Gupta S, Leal T, Kwiatkowski D, Mak R, Adib E, Naqash A, Goldberg S. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. Journal Of Thoracic Oncology 2024, 19: 928-940. PMID: 38278303, DOI: 10.1016/j.jtho.2024.01.012.Peer-Reviewed Original ResearchTreatment-related adverse eventsConcurrent chemoradiationConsolidation therapyConsolidation durvalumabOverall survivalEGFR-mutant non-small-cell lung cancerAny-grade TRAEsCommon Terminology Criteria for Adverse Events versionFollow-upReal-world progression-free survivalObservational cohortNon-small-cell lung cancerPatients treated with osimertinibEGFR tyrosine kinase inhibitorsMedian duration of treatmentMulticenter retrospective cohort studyMultivariate Cox regression analysisDefinitive concurrent chemoradiationInternational retrospective analysisOptimal consolidation therapySensitive EGFR mutationsTreated with durvalumabAdverse Events versionProgression-free survivalStage III NSCLC
2022
Immunotherapy in non-small cell lung cancer: Past, present, and future directions
Punekar S, Shum E, Grello C, Lau S, Velcheti V. Immunotherapy in non-small cell lung cancer: Past, present, and future directions. Frontiers In Oncology 2022, 12: 877594. PMID: 35992832, PMCID: PMC9382405, DOI: 10.3389/fonc.2022.877594.Peer-Reviewed Original ResearchNon-small cell lung cancerImmune checkpoint blockadeProgression-free survivalCell lung cancerLung cancerAnti-cytotoxic T-lymphocyte-associated protein 4 antibodyAnti-programmed death-1 antibodyDeath-1 antibodyFuture of immunotherapyOverall survival benefitProtein 4 antibodyViable therapeutic approachIdentification of biomarkersFree survivalCheckpoint blockadeDurable responsesSurvival benefitModulating therapiesCombination therapyClinical trialsTherapeutic approachesImmunotherapyFuture careLigand antibodyCellular therapy
2021
Response to immune checkpoint inhibitor rechallenge after high-grade immune related adverse events in patients with advanced melanoma
Shah P, Punekar S, Pavlick A. Response to immune checkpoint inhibitor rechallenge after high-grade immune related adverse events in patients with advanced melanoma. Melanoma Research 2021, 31: 242-248. PMID: 33741813, DOI: 10.1097/cmr.0000000000000730.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsProgression-free survivalHigh-grade immune-related adverse eventsImmune checkpoint inhibitorsOverall survivalDisease progressionAdverse eventsAdvanced melanomaInitial irAEImmune checkpoint inhibitor rechallengeImmune related adverse eventsMedian progression-free survivalUnresectable stage III melanomaMedian overall survivalPercent of patientsRelated adverse eventsStage III melanomaLimited clinical evidenceRisk-benefit profileContinuation of treatmentNYU Langone HealthICI initiationICI rechallengeICI therapyCheckpoint inhibitors
2012
Radical Pleurectomy and Intraoperative Photodynamic Therapy for Malignant Pleural Mesothelioma
Friedberg J, Culligan M, Mick R, Stevenson J, Hahn S, Sterman D, Punekar S, Glatstein E, Cengel K. Radical Pleurectomy and Intraoperative Photodynamic Therapy for Malignant Pleural Mesothelioma. The Annals Of Thoracic Surgery 2012, 93: 1658-1667. PMID: 22541196, PMCID: PMC4394024, DOI: 10.1016/j.athoracsur.2012.02.009.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCohort StudiesCombined Modality TherapyDisease-Free SurvivalFemaleFollow-Up StudiesHumansImmunohistochemistryIntraoperative CareMaleMesotheliomaMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPhotochemotherapyPleuraPleural NeoplasmsRisk AssessmentSurvival AnalysisTime FactorsTreatment OutcomeConceptsProgression-free survivalMacroscopic complete resectionRadical pleurectomyIntraoperative photodynamic therapyNonepithelial subtypeMedian survivalComplete resectionEpithelial subtypesStage III/IV diseaseMedian progression-free survivalStage III/IV cancerPhotodynamic therapyLung-sparing approachLung-sparing surgeryMalignant pleural mesotheliomaPostoperative mortalitySystemic therapyPleural mesotheliomaEpithelial diseasePatientsMesotheliomaSubtypesTherapyMonthsSurvival